Ngā hua rapu - Zhe-Ran Liu

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial mā Zhi-gong Wei, Hui-jiao Chen, De-juan Wang, Zheng Jiang, Yi-yan Pei, Le-yu Li, Feng Wang, Jing Jin, Zhe-ran Liu, Fei Chen, Jun Liu, Xing-chen Peng

Whiwhi kuputuhi katoa

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial mā Yu-Chun Zhu, Zhi-Gong Wei, Jing-Jing Wang, Yi-Yan Pei, Jing Jin, Dong Li, Zhi-Hui Li, Zhe-Ran Liu, Yu Min, Rui-Dan Li, Li Yang, Ji-Yan Liu, Qiang Wei, Xing-Chen Peng

Whiwhi kuputuhi katoa

Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma mā Hong-Shuai Li, Ruo Tang, Hua-Shan Shi, Zi-Jian Qin, Xiao-Yang Zhang, Yun-Fei Sun, Zhi-Gong Wei, Chao-Fan Ma, Liu Yang, Ye Chen, Zhe-Ran Liu, Li-Li Zhu, Wen Yang, Li Yang, Ai-Ning Xu, Zhuo Zhang, Shu-Qing Liao, Jin-Shui Shi, Jian-Jun Deng, Xiao-Zhong He, Xing-Chen Peng

Whiwhi kuputuhi katoa